Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 62

1.

Discovery of Clinical Candidate 4-[2-(5-Amino-1H-pyrazol-4-yl)-4-chlorophenoxy]-5-chloro-2-fluoro-N-1,3-thiazol-4-ylbenzenesulfonamide (PF-05089771): Design and Optimization of Diaryl Ether Aryl Sulfonamides as Selective Inhibitors of NaV1.7.

Swain NA, Batchelor D, Beaudoin S, Bechle BM, Bradley PA, Brown AD, Brown B, Butcher KJ, Butt RP, Chapman ML, Denton S, Ellis D, Galan SRG, Gaulier SM, Greener BS, de Groot MJ, Glossop MS, Gurrell IK, Hannam J, Johnson MS, Lin Z, Markworth CJ, Marron BE, Millan DS, Nakagawa S, Pike A, Printzenhoff D, Rawson DJ, Ransley SJ, Reister SM, Sasaki K, Storer RI, Stupple PA, West CW.

J Med Chem. 2017 Aug 24;60(16):7029-7042. doi: 10.1021/acs.jmedchem.7b00598. Epub 2017 Aug 10.

PMID:
28682065
2.

Discovery of a Series of Indazole TRPA1 Antagonists.

Pryde DC, Marron BE, West CW, Reister S, Amato G, Yoger K, Antonio B, Padilla K, Cox PJ, Turner J, Warmus JS, Swain NA, Omoto K, Mahoney JH, Gerlach AC.

ACS Med Chem Lett. 2017 May 18;8(6):666-671. doi: 10.1021/acsmedchemlett.7b00140. eCollection 2017 Jun 8.

PMID:
28626530
3.

Type of Referral, Dialysis Start and Choice of Renal Replacement Therapy Modality in an International Integrated Care Setting.

Marrón B, Ostrowski J, Török M, Timofte D, Orosz A, Kosicki A, Całka A, Moro D, Kosa D, Redl J, Qureshi AR, Divino-Filho JC; d.PD Clinics Eastern Europe.

PLoS One. 2016 May 26;11(5):e0155987. doi: 10.1371/journal.pone.0155987. eCollection 2016.

4.

Subtype-Selective Small Molecule Inhibitors Reveal a Fundamental Role for Nav1.7 in Nociceptor Electrogenesis, Axonal Conduction and Presynaptic Release.

Alexandrou AJ, Brown AR, Chapman ML, Estacion M, Turner J, Mis MA, Wilbrey A, Payne EC, Gutteridge A, Cox PJ, Doyle R, Printzenhoff D, Lin Z, Marron BE, West C, Swain NA, Storer RI, Stupple PA, Castle NA, Hounshell JA, Rivara M, Randall A, Dib-Hajj SD, Krafte D, Waxman SG, Patel MK, Butt RP, Stevens EB.

PLoS One. 2016 Apr 6;11(4):e0152405. doi: 10.1371/journal.pone.0152405. eCollection 2016.

5.

Voltage gated sodium channels as drug discovery targets.

Bagal SK, Marron BE, Owen RM, Storer RI, Swain NA.

Channels (Austin). 2015;9(6):360-6. doi: 10.1080/19336950.2015.1079674. Review.

6.

Recent progress in sodium channel modulators for pain.

Bagal SK, Chapman ML, Marron BE, Prime R, Storer RI, Swain NA.

Bioorg Med Chem Lett. 2014 Aug 15;24(16):3690-9. doi: 10.1016/j.bmcl.2014.06.038. Epub 2014 Jun 21. Review.

7.

Voltage sensor interaction site for selective small molecule inhibitors of voltage-gated sodium channels.

McCormack K, Santos S, Chapman ML, Krafte DS, Marron BE, West CW, Krambis MJ, Antonio BM, Zellmer SG, Printzenhoff D, Padilla KM, Lin Z, Wagoner PK, Swain NA, Stupple PA, de Groot M, Butt RP, Castle NA.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):E2724-32. doi: 10.1073/pnas.1220844110. Epub 2013 Jul 1.

8.

Pharmacovigilance as a tool for safety and monitoring: a review of general issues and the specific challenges with end-stage renal failure patients.

Jacob D, Marrón B, Ehrlich J, Rutherford PA.

Drug Healthc Patient Saf. 2013 Apr 15;5:105-12. doi: 10.2147/DHPS.S43104. Print 2013.

9.

Effect of self-administered intraperitoneal bemiparin on peritoneal transport and ultrafiltration capacity in peritoneal dialysis patients with membrane dysfunction. A randomized, multi-centre open clinical trial.

Del Peso G, Bajo MA, Fontán MP, Martínez J, Marrón B, Selgas R; Group of Study on Bemidextrin.

Nephrol Dial Transplant. 2012 May;27(5):2051-8. doi: 10.1093/ndt/gfr546. Epub 2011 Oct 12.

PMID:
21993377
10.

Discovery and biological evaluation of potent, selective, orally bioavailable, pyrazine-based blockers of the Na(v)1.8 sodium channel with efficacy in a model of neuropathic pain.

Scanio MJ, Shi L, Drizin I, Gregg RJ, Atkinson RN, Thomas JB, Johnson MS, Chapman ML, Liu D, Krambis MJ, Liu Y, Shieh CC, Zhang X, Simler GH, Joshi S, Honore P, Marsh KC, Knox A, Werness S, Antonio B, Krafte DS, Jarvis MF, Faltynek CR, Marron BE, Kort ME.

Bioorg Med Chem. 2010 Nov 15;18(22):7816-25. doi: 10.1016/j.bmc.2010.09.057. Epub 2010 Sep 29.

PMID:
20965738
11.

'Reality and desire' in the care of advanced chronic kidney disease.

Marrón B, Craver L, Remón C, Prieto M, Gutiérrez JM, Ortiz A.

NDT Plus. 2010 Oct;3(5):431-5. doi: 10.1093/ndtplus/sfq116. Epub 2010 Jun 28.

12.

Subtype-selective Na(v)1.8 sodium channel blockers: identification of potent, orally active nicotinamide derivatives.

Kort ME, Atkinson RN, Thomas JB, Drizin I, Johnson MS, Secrest MA, Gregg RJ, Scanio MJ, Shi L, Hakeem AH, Matulenko MA, Chapman ML, Krambis MJ, Liu D, Shieh CC, Zhang X, Simler G, Mikusa JP, Zhong C, Joshi S, Honore P, Roeloffs R, Werness S, Antonio B, Marsh KC, Faltynek CR, Krafte DS, Jarvis MF, Marron BE.

Bioorg Med Chem Lett. 2010 Nov 15;20(22):6812-5. doi: 10.1016/j.bmcl.2010.08.121. Epub 2010 Sep 18.

PMID:
20855211
13.

A-887826 is a structurally novel, potent and voltage-dependent Na(v)1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats.

Zhang XF, Shieh CC, Chapman ML, Matulenko MA, Hakeem AH, Atkinson RN, Kort ME, Marron BE, Joshi S, Honore P, Faltynek CR, Krafte DS, Jarvis MF.

Neuropharmacology. 2010 Sep;59(3):201-7. doi: 10.1016/j.neuropharm.2010.05.009. Epub 2010 Jun 1.

PMID:
20566409
14.

A deletion mutation in bovine SLC4A2 is associated with osteopetrosis in Red Angus cattle.

Meyers SN, McDaneld TG, Swist SL, Marron BM, Steffen DJ, O'Toole D, O'Connell JR, Beever JE, Sonstegard TS, Smith TP.

BMC Genomics. 2010 May 27;11:337. doi: 10.1186/1471-2164-11-337.

15.

A study of hydrogenated carbon fibers by scanning electron microscopy and confocal laser scanning microscopy.

de la Cal AM, Aguado-Serrano J, Rojas-Cervantes ML, Adame EV, Marron BS, Rosende AC, Nevshupa R.

Microsc Res Tech. 2009 Jun;72(6):447-53. doi: 10.1002/jemt.20690.

PMID:
19208389
16.

[Theoretical bases for the proposal of a randomized, controlled, open label clinical trial to assess the efficacy of adding bemiparin to the icodextrin solution in patients on peritoneal dialysis with peritoneal transport disorders [FRIAT-BEM-2005-01]].

Selgas R, Del Peso G, Sánchez Villanueva R, Aroeira LS, Fernández Perpén A, Ortiz A, Ruiz Ortega M, Sánchez-Tomero JA, Martínez J, Marrón B, Bajo MA.

Nefrologia. 2008;28 Suppl 6:51-8. Spanish.

17.

Additive effects of soluble TWEAK and inflammation on mortality in hemodialysis patients.

Carrero JJ, Ortiz A, Qureshi AR, Martín-Ventura JL, Bárány P, Heimbürger O, Marrón B, Metry G, Snaedal S, Lindholm B, Egido J, Stenvinkel P, Blanco-Colio LM.

Clin J Am Soc Nephrol. 2009 Jan;4(1):110-8. doi: 10.2215/CJN.02790608. Epub 2008 Oct 22.

18.

Block of Nav1.8 by small molecules.

Krafte DS, Chapman M, Marron B, Atkinson R, Liu Y, Ye F, Curran M, Kort M, Jarvis MF.

Channels (Austin). 2007 May-Jun;1(3):152-3. Epub 2007 Jul 18.

PMID:
18690030
19.

Creating porcine biomedical models through recombineering.

Rogatcheva MM, Rund LA, Swanson KS, Marron BM, Beever JE, Counter CM, Schook LB.

Comp Funct Genomics. 2004;5(3):262-7. doi: 10.1002/cfg.404.

20.

Icodextrin does not impact infectious and culture-negative peritonitis rates in peritoneal dialysis patients: a 2-year multicentre, comparative, prospective cohort study.

Vychytil A, Remón C, Michel C, Williams P, Rodríguez-Carmona A, Marrón B, Vonesh E, van der Heyden S, Divino Filho JC; Extraneal Peritonitis Study Group.

Nephrol Dial Transplant. 2008 Nov;23(11):3711-9. doi: 10.1093/ndt/gfn322. Epub 2008 Jun 13.

Supplemental Content

Loading ...
Support Center